Teva to stop selling migraine drug patch Zecuity after patients report burns and scars

Teva Pharmaceutical Industries Ltd. said Monday it would voluntarily stop selling, marketing and distributing migraine drug patch Zecuity after reports of burns and scars in patients. Teva also said it would recall the product from pharmacies and work with the Food and Drug Administration to better understand what happened. Shares were down 0.7% in pre-market trade. Teva stock was down 19.7% in the year to date, compared with a 2.6% increase in the S&P 500 .

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.